KYPROLIS ® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
Results Highlighted During Oral Presentation at ASH 2017
Addition of KYPROLIS to Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone
Regulatory Applications Submitted in the U.S. to add ASPIRE Overall Survival Results to KYPROLIS Label
THOUSAND OAKS, Calif., Dec. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new results showing the positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of OS, demonstrating that the addition of KYPROLIS® (carfilzomib) to len...
Source: Amgen News Release - December 11, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Response to Lenalidomide Often Suboptimal in MDS/MPN - RS - T
Hematological responses seen in three patients with MDS/MPN - RS - T, but the responses not durable (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 1, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news
Lenalidomide Boosts Overall Survival After Stem Cell Tx (CME/CE)
(MedPage Today) -- Now considered a standard of care for multiple myeloma patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 10, 2017 Category: Hematology Source Type: news
TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement
Roche: Based on emerging safety data from clinical trials evaluating pembrolizumab in combination with either lenalidomide or pomalidomide in multiple myeloma, the FDA has requested that a Phase Ib and a Phase Ib/II TECENTRIQ study be placed on partial clinical hold. (Source: Roche Investor Update)
Source: Roche Investor Update - September 15, 2017 Category: Pharmaceuticals Source Type: news
Survival Benefit in Myeloma With Lenalidomide Maintenance After Transplant
Patients with newly diagnosed multiple myeloma treated with lenalidomide maintenance therapy after undergoing autologous stem-cell transplantation had significantly improved overall survival compared with observation or placebo. (Source: CancerNetwork)
Source: CancerNetwork - August 17, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news
Roswell Park-Led Analysis Shows Survival Benefit of Lenalidomide...
New research analysis published in JCO definitively shows an overall survival benefit from ongoing treatment with lenalidomide for patients with multiple myeloma who have already received bone marrow...(PRWeb August 15, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14605233.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 15, 2017 Category: Pharmaceuticals Source Type: news
Maintenance Lenalidomide Improves PFS in DLBCL (CME/CE)
(MedPage Today) -- No difference in OS compared with placebo after a median follow-up of 52 months (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 4, 2017 Category: Primary Care Source Type: news
Revlimid drives Celgene profit beat; raises EPS forecast
(Reuters) - Celgene Corp rode its flagship multiple myeloma drug Revlimid and a rebound in sales of Otezla for psoriasis to a modestly higher-than-expected second-quarter profit and raised its full-year earnings forecast on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - July 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Celgene to Pay $280 Million to Settle Off-label Marketing Case Celgene to Pay $280 Million to Settle Off-label Marketing Case
The U.S. Justice Department said on Tuesday that Celgene Corp had agreed to pay $280 million to settle a lawsuit that accused the company of promoting its cancer drugs Revlimid and Thalomid for off-label uses.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs
The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers. (Source: NYT Health)
Source: NYT Health - July 26, 2017 Category: Consumer Health News Authors: KATIE THOMAS Tags: Drugs (Pharmaceuticals) Suits and Litigation (Civil) Thalidomide (Drug) Celgene Corporation Whistle-Blowers Cancer Food and Drug Administration Source Type: news
FDA Halts Pembrolizumab Trials in Multiple Myeloma
The US Food and Drug Administration (FDA) placed a clinical hold on three trials of the PD-1 inhibitor pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma: KEYNOTE-183, KEYNOTE-185, and KEYNOTE-023. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news
Amgen ’s multiple myeloma drug shows positive outcome in Phase III trial
Amgen has reported a positive outcome from the Phase III clinical trial (ASPIRE) of Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) to treat relapsed multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 13, 2017 Category: Pharmaceuticals Source Type: news
Second Phase 3 Study Shows KYPROLIS ® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone
Patients Treated With the KYPROLIS-Based Regimen Survived 7.9 Months Longer Than Patients on Lenalidomide and Dexamethasone
KYPROLIS-Based Regimens Are the First and Only to Demonstrate Improved Overall Survival Versus Today's Standards of Care in Two Phase 3 Studies in Relapsed Multiple Myeloma
THOUSAND OAKS, Calif., July 12, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of o...
Source: Amgen News Release - July 12, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
